SAT-452 Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label Study
Tânia A.S.S. Bachega(Universidade Federal de São Paulo), Umasuthan Srirangalingam(University College Hospital), Jamie Marko(National Institutes of Health Clinical Center), Alejandro Ayala(Instituto Tecnológico de Morelia), Alan Krasner(Takeda (United States)), Mônica R. Gadelha(Universidade Federal do Rio de Janeiro), Nicole Reisch(LMU Klinikum), Eduardo De La Torre Ames(Crinetics Pharmaceuticals (United States)), Richard J. Auchus(University of Michigan), Darío Bruera(Misericordia University), Yang Wu(Crinetics Pharmaceuticals (United States))
Cited by 1
Related Papers
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
|Cancer Cell|2017|791
Cytochrome b 5 Augments the 17,20-Lyase Activity of Human P450c17 without Direct Electron Transfer
|Journal of Biological Chemistry|1998|543
An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence
|Hormone Research in Paediatrics|2017|451
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
|The Journal of Clinical Endocrinology & Metabolism|2014|394